1. Hong Kong Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
United Laboratories International Holdings Ltd.

United Laboratories International Holdings Ltd.

6.90
HKD
-0.32
(-4.43%)
22.87BMarket Cap
Mar 30Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.67
3.95
3.96
3.74
4.2
4.6
5.12
4.97
5.27
6.23
7.56
7.57
7.01
- -
Basic EPS, GAAP
0.02
0.33
0.06
-0.17
0.05
0.42
0.39
0.4
0.54
0.87
1.49
1.46
1.11
- -
Free Cash Flow per Basic Share
-0.27
0.22
0.53
0.37
0.18
0.4
0.82
0.58
0.57
0.67
0.54
0.73
0.45
- -
Dividend per Share
- -
- -
- -
- -
- -
0.05
0.06
0.07
0.12
0.15
0.32
0.56
0.55
- -
Book Value per Share
3.11
3.43
3.46
3.29
3.34
3.73
4.06
4.68
5.09
5.84
7.01
7.92
8.82
8.82
Tangible Book Value per Share
3
3.39
3.4
3.19
3.25
3.51
3.97
4.6
5.02
5.78
6.93
7.8
8.67
8.67
Basic Weighted Avg Shares
1,627
1,627
1,627
1,627
1,627
1,634
1,640
1,766
1,840
1,820
1,817
1,817
1,885
1,895
Sales/Revenue/Turnover
5,977
6,421
6,443
6,078
6,827
7,511
8,393
8,772
9,703
11,334
13,740
13,759
13,211
- -
Operating Margin (%)
9.97
19.62
12.49
7.97
11.24
13.49
12.95
15
15.12
18.45
23.94
22.65
18.8
- -
Depreciation Expense
449
570
688
716
790
748
676
614
621
552
566
616
650
- -
Net Income, GAAP
38
545
92
-272
82
683
642
703
988
1,581
2,701
2,660
2,086
- -
Effective Tax Rate (%)
94.67
- -
53.12
- -
- -
13.98
23.75
20.56
17.72
21.22
19.24
19.19
17.68
- -
Profit Margin (%)
0.63
8.48
1.43
-4.48
1.2
9.09
7.65
8.01
10.18
13.95
19.66
19.33
15.79
- -
Working Capital
-2,595
-1,831
-2,268
-968
976
182
2,255
3,365
3,451
5,482
7,160
7,298
8,390
8,390
LT Debt
1,692
1,730
1,194
1,839
2,992
1,591
2,423
1,303
228
1,100
1,303
2,321
2,880
2,880
Total Equity
5,065
5,573
5,626
5,347
5,442
6,122
6,672
8,612
9,340
10,609
12,748
14,435
17,475
17,475
Return on Invested Capital (%)
-0.06
- -
3.24
- -
- -
8.11
8.65
8.9
8.38
12.8
18.69
15.11
9.88
- -
Return on Capital (%)
0.43
- -
2.04
- -
- -
8.85
7.77
7.55
9.42
13.57
20.17
16.89
10.73
- -
Return on Common Equity (%)
0.75
10.24
1.65
-4.96
1.52
11.81
10.03
9.2
11.01
15.85
23.14
19.61
13.13
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
ST Debt
835
1,394
2,111
LT Borrowings
2,308
3,722
2,873
LT Finance Leases
13
10
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,817
1,817
1,973
Market Capitalization
21,103
24,907
20,548

Working Capital

CNY

•

in mil. unless spec.
Dec'24
Jun'25
Dec'25
Total Current Assets
16,071
18,303
18,470
Cash, Cash Equivalents & STI
6,330
9,014
10,606
Accounts Receivable, Net
2,393
2,255
2,217
Inventories
2,434
2,776
2,369
Total Current Liabilities
8,773
9,706
10,079
Payables & Accruals
- -
- -
- -
ST Debt
835
1,394
2,111
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
12.39%
15.3%
21.06%
Free Cash Flow
12.11%
-0.35%
-35.63%
Net Income, GAAP
36.24%
29.66%
-21.57%
Sales/Revenue/Turnover
7.77%
8.96%
-3.99%
Total Cash Common Dividend
- -
57.3%
2.45%

Semi-annual Revenue

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
13,740
2024
- -
- -
13,759
2025
- -
- -
13,211

Semi-annual Earnings Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
1.49
2024
- -
- -
1.46
2025
- -
- -
1.11

Semi-annual Dividends Per Share

CNY

•

in mil. unless spec.

Year

H1
H2
FY
2023
- -
- -
0.32
2024
- -
- -
0.56
2025
- -
- -
0.55

Company Description

Company Profile APIChatGPT
CEO
Hoi Shan Tsoi
Full Time Employees
18,000
Sector
Health technology
Industry
Pharmaceuticals: major
Address
6 Fuk Wang Street Hong Kong Hong Kong
IPO Date
Jun 15, 2007
Website
tul.com.cn
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
The United Laboratories International Holdings Limited functions as an investment holding company, primarily dedicated to the research, advancement, production, supply, and commercialization of pharmaceutical goods. The enterprise organizes its activities across three main divisions: Bulk Medicine, Intermediate Products, and Finished Products. Its comprehensive product range includes a variety of finished pharmaceuticals such as oral antibiotics, injectable antimicrobial agents, remedies for colds, cough suppressants, ophthalmic solutions, antiviral medications, treatments for hepatitis B, diabetes management drugs including insulin series, external dermatological preparations, cardiovascular and cerebrovascular therapies, nervous system medications, vitamins, and specialized veterinary drugs, alongside empty gelatin capsules. Additionally, the company produces active pharmaceutical ingredients and intermediate compounds like 6-aminopenicillanic acid. Beyond its core pharmaceutical manufacturing, the Group also engages in the production and distribution of soft capsule casings, manages its intellectual property through trademarks, trades in pharmaceutical products, and offers various management services. Operating with a global footprint, the company serves markets across the People's Republic of China, Europe, India, the Middle East, South America, and other Asian territories, maintaining an international presence. Recent strategic developments highlight an ongoing commitment to innovation, marked by substantial investments in research and development, with numerous new drug candidates progressing through clinical trials, particularly in endocrine, metabolic, and anti-infective fields. Notably, the Group has recently entered into significant licensing agreements for its innovative drug candidates, demonstrating its capacity for global partnerships. Founded in 1990, the company's headquarters are situated in Yuen Long, Hong Kong.